<DOC>
	<DOCNO>NCT02121613</DOCNO>
	<brief_summary>The aim study support efficacy Permixon 160 mg b.i.d . treat subject symptomatic Benign Prostatic Hyperplasia ( BPH ) , compare placebo , use Tamsulosine LP 0.4 mg reference treatment .</brief_summary>
	<brief_title>PERmixon® LUTS Evaluation Study ( PERLES )</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Permixon</mesh_term>
	<criteria>Male subject Between 45 85 year old Subject bothersome lower urinary tract symptom ( LUTS ) due BPH frequency ( daytime night time ) , urgency , sensation incomplete voiding , delay urination weak stream Subject naive prior treatment LUTS due BPH Prostate enlargement digital rectal examination ( DRE ) suggestive BPH IPSS &gt; 12 enrolment visit inclusion visit QoL IPSS score ≥ 3 evaluated enrolment visit inclusion visit Urological history urethral stricture disease and/or bladder neck disease , active ( enrolment and/or inclusion recurrent urinary tract infection , stone bladder urethra ) Any neurologic psychiatric disease/disorder interfere detrusor sphincter muscle Insulindependent diabetes mellitus noncontrolled non insulindependent diabetes mellitus Known severe renal insufficiency creatinine clearance &lt; 30 ml/mn Known liver insufficiency clinically significant abnormal liver function test History , concomitant , cardiac arrhythmia angina pectoris Orthostatic hypotension enrolment inclusion visit Known hypersensitivity one constituent study drug Is participate another clinical trial</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>